leadf
logo-loader
viewProactive Group

UniQure shares up in premarket after hemophelia B early stage trial shows positive results

UniQure plans to start a pivotal study in 2018 with AMT-061, which combines an AAV5 vector with the FIX-Padua mutant

blood
The condition can cause life-threatening episodes of external and internal bleeding and requires regular injections of plasma-derived human Factor IX.

UniQure N.V. shares (NASDAQ:QURE) were on the uptick in premarket trade after an early-stage trial of a treatment for severe hemophelia B recorded positive results.

In a statement, the company said the 18-month follow-up data from a Phase I/II trial of AMT-060 in the second-dose cohort found "substantial improvement" in disease state in all five patients, and that all those who previous required routine prophylactic FIX infusions were able to stop them.

Pivotal study in 2018

UniQure plans to start a pivotal study in 2018 with AMT-061, which combines an AAV5 vector with the FIX-Padua mutant.

AMT-061 and AMT-060 are identical in structure apart from two nucleotide substitutions in the coding sequence for FIX.

Hemophelia is an inherited disease that affects males. It stops their blood from clotting after a bleed.

The condition can cause life-threatening episodes of external and internal bleeding and requires regular injections of plasma-derived human Factor IX.

The data were presented to the 58th American Society of Hematology (ASH) annual meeting in Atlanta, Georgia on Monday morning.

"We continue to observe a therapeutic benefit from AMT-060 that is clearly superior to patients' previous prophylactic FIX replacement therapy regimen, with stable elevations in Factor IX levels and a cessation of spontaneous bleeds," said Professor Frank W.G. Leebeek, of the Erasmus University Medical Center in Rotterdam.

In premarket, uniQure shares were up 3.25% at US$18.40.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Snowline Gold looking to unlock potential of Einarson and Rouge projects in...

Snowline Gold (CSE: SGD) CEO Nikolas Matysek joined Steve Darling from Proactive to share more details about the company that will begin trading soon on the CSE under the ticker SGD. Matysek talks about that and also about the formation of the company. Matysek also shared with Proactive about...

40 minutes ago

2 min read